Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar 11;10(3):e0118241.
doi: 10.1371/journal.pone.0118241. eCollection 2015.

Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial

Alessia Verduri  1 , Fabrizio Luppi  1 , Roberto D'Amico  2 , Sara Balduzzi  2 , Roberto Vicini  2 , Anna Liverani  3 , Valentina Ruggieri  1 , Mario Plebani  3 , Maria Pia Foschino Barbaro  4 , Antonio Spanevello  5 , Giorgio Walter Canonica  6 , Alberto Papi  7 , Leonardo Michele Fabbri  1 , Bianca Beghè  1 ; FARM58J2XH Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial

Alessia Verduri et al. PLoS One. .

Abstract

Background: The duration of antibiotic treatment of exacerbations of COPD (ECOPD) is controversial. Serum procalcitonin (PCT) is a biomarker of bacterial infection used to identify the cause of ECOPD.

Methods and findings: We investigated whether a PCT-guided plan would allow a shorter duration of antibiotic treatment in patients with severe ECOPD. For this multicenter, randomized, non-inferiority trial, we enrolled 184 patients hospitalized with ECOPD from 18 hospitals in Italy. Patients were assigned to receive antibiotics for 10 days (standard group) or for either 3 or 10 days (PCT group). The primary outcome was the rate of ECOPD at 6 months. Having planned to recruit 400 patients, we randomized only 183: 93 in the PCT group and 90 in the standard group. Thus, the completed study was underpowered. The ECOPD rate at 6 months between PCT-guided and standard antibiotic treatment was not significant (% difference, 4.04; 90% confidence interval [CI], -7.23 to 15.31), but the CI included the non-inferiority margin of 15. In the PCT-guided group, about 50% of patients were treated for 3 days, and there was no difference in primary or secondary outcomes compared to patients treated for 10 days.

Conclusions: Although the primary and secondary clinical outcomes were no different for patients treated for 3 or 10 days in the PCT group, the conclusion that antibiotics can be safely stopped after 3 days in patients with low serum PCT cannot be substantiated statistically. Thus, the results of this study are inconclusive regarding the noninferiority of the PCT-guided plan compared to the standard antibiotic treatment. The study was funded by Agenzia Italiana del Farmaco (AIFA-FARM58J2XH). Clinical trial registered with www.clinicaltrials.gov (NCT01125098).

Trial registration: ClinicalTrials.gov NCT01125098.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: LMF received payment for consultancy from: Almirall, Boehringer LMF received payment for consultancy from: Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Euromediform, GlaxoSmithKline, Merck Sharp & Dhome, Mundipharma International, Novartis, Takeda, Pearl Therapeutics, Sterna, Peer Voice Europe, OM Pharma, TEVA; payment for lectures, advisory boards or travel expenses reimbursements from: AstraZeneca, Dey Pharma, Grünenthal GmbH, Mundipharma International, Novartis, Roche, Genetech Inc. AS declares he received personal benefits or personal travel grants or expenses for conferences from Boehringer, Novartis, Astrazeneca, Guidotti, Malesci, Almirall, Gsk, Mundipharma, Pfizer. AP gave presentations at symposia sponsored by, received research grants from, or served on scientific advisory boards of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Dompè, GlaxoSmithKline, Guidotti, Menarini, MSD, Mundipharma, Novartis, Pfizer, Takeda, TEVA, Zambon. SB, VR, RV, MPFB, GWC, MP, FL, BB, AV, AL, RDA declare they have no conflicts. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Trial protocol. Severe disease = respiratory failure or clinical instability.
Fig 2
Fig 2. Trial profile: screening, enrollment, randomization, and follow-up.
Fig 3
Fig 3. Percentage of patients with at least one exacerbation during the 6 months of follow-up in the three groups: patients who received antibiotics for 3 days (PCT 3 days) or 10 days (PCT 10 days) according to a PCT-guided plan, or for 10 days according to the standard plan. P = not significant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Donaldson GC, Wedzicha JA (2006) COPD exacerbations. 1: Epidemiology. Thorax 61: 164–168. - PMC - PubMed
    1. Hurst JR (2011) Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184: 625–626. 10.1164/rccm.201106-1136ED - DOI - PubMed
    1. White AJ, Gompertz S, Stockley RA (2003) Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 58: 73–80. - PMC - PubMed
    1. Miravitlles M, Anzueto A (2013) Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 188: 1052–1057. 10.1164/rccm.201302-0289PP - DOI - PubMed
    1. Albert R, Connett J, Bailey W, Casaburi R, Cooper JJ, et al. (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365: 689–698. 10.1056/NEJMoa1104623 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data